Navigation Links
Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook

MORRISTOWN, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its fourth quarter 2010 financial results on Tuesday, February 23, 2010 prior to the open of the U.S. financial markets.  The Company will also host a conference call and webcast at 8:30 a.m. Eastern Standard Time on February 23, 2010 to discuss its financial results and provide an update on the Company's outlook for 2010.  The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Standard Time on March 5, 2010.  The replay may be accessed by dialing (800) 642-1687 and entering pass code 51552597.  From international locations, the replay may be accessed by dialing (706) 645-9291 and entering the same pass code.  To access the webcast, go to Watson's Investor Relations Web site at  A replay of the webcast will also be available.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press releases and other company information, visit the Watson Web site at


SOURCE Watson Pharmaceuticals, Inc.



SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Completes Acquisition of Eden Biodesign
2. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
3. Watson Files FDA Application for Generic Rozerem(R)
4. Watson to Present at Credit Suisse Healthcare Conference
5. Watson and Barr Settle Lawsuit Over Oxytrol(R)
6. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
7. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
8. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
9. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
10. Watson Launches Generic Biaxin(R) XL
11. Dynatronics to Release Second Quarter Results Monday, February 1, 2010; Conference Call Set for 1:30 p.m. ET
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 As enforcement of the ... Security Act (DSCSA) approaches, InfiniTrak announced ... pharmacies comply with looming FDA regulations. ... entering endorsement agreements with State Pharmacy Associations, an ... organization (PSAO) to exclusively provide the InfiniTrak track-and-trace ...
(Date:12/1/2015)... CLEVELAND , Dec. 1, 2015   ... innovation firm, today announced the publication of a ... Entering the Direct-to-Consumer Medical Market". The whitepaper gives ... roadmap for successfully penetrating this lucrative segment. ... purchase healthcare products to manage their own health, ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... It’s official: ... a tattoo — a number even greater among Millennials (a whopping one in three ... more and more people who are dissatisfied with their ink. In fact, RealSelf ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... in the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience ... are often catastrophic contributors to diseases of the diabetic foot. The American ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many ... the film for accurate interpretation by the radiologist. The marking utensils are so ... Sacramento, Calif., has found a way to alleviate this problem. , He developed ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... that it has been selected as a finalist in this year’s Fierce Innovation ... FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the category of ...
Breaking Medicine News(10 mins):